JME Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Molecular Endocrinology (2006) 37 13-23    DOI: 10.1677/jme.1.01955
© 2006 Society for Endocrinology

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frommer, K. W
Right arrow Articles by Elmlinger, M. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frommer, K. W
Right arrow Articles by Elmlinger, M. W

IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T

Klaus W Frommer, Katharina Reichenmiller1, Burkhardt S Schutt, Andreas Hoeflich2, Michael B Ranke, Gabriele Dodt3 and Martin W Elmlinger

Pediatric Endocrinology Section, University Children’s Hospital, 72076 Tuebingen, Germany
1 School of Dental Medicine at the University of Tuebingen, Department of Conservative Dentistry, 72076 Tuebingen, Germany
2 Institute of Molecular Animal Breeding and Biotechnology/Gene Center, Ludwig-Maximilians-University, 81377 Munich, Germany
3 Institute for Biochemistry, Department of Cell Biochemistry, Eberhard-Karls-University, 72076 Tuebingen, Germany

(Requests for offprints should be addressed to M W Elmlinger; Email: martin.elmlinger{at}altanapharma.com)

There is evidence that insulin-like growth factor-binding protein (IGFBP-2), a modulator of the actions of IGFs, also has IGF-independent effects in human tumor cell lines. These involve specific binding of IGFBP-2 to {alpha}5ß1-integrin, followed by alterations in the phosphorylation status of downstream signaling molecules. Previously, IGFBP-2 has also been shown to be associated with cell proliferation, adhesion and migration. Here, we investigated direct effects of IGFBP-2 on apoptosis and alterations in the expression of related proteins. The breast cancer cell line Hs578T, which shows no IGFBP-2 production of its own and is independent of the IGF-I receptor, was treated with human recombinant IGFBP-2 in order to study the changes in gene expression induced by IGFBP-2. The methods employed for this purpose were oligonucleotide microarrays, real-time RT-PCR, western blotting, and immunoassays. Out of the 440 genes covered by the Oligo GEArray Human Cancer Microarray OHS-802, the expression of 77 genes was directly influenced by IGFBP-2. By the use of real-time quantitative RT-PCR, the gene expression of Nuclear Factor (NF){kappa}B, p53, transforming growth factor ß (TGF ß-1), LAMB1 (Laminin, Beta 1), Bcl-2, and IIp45 was found to be significantly upregulated (by 1.2- to 3.05-fold; all P < 0.001). Accordingly, NF{kappa}B, p53, and TGF ß-1 proteins, as measured by Western blotting and immunoassay, were upregulated > 1.5-fold. By using an ELISA-based and a flow cytometry-based apoptosis assay, IGFBP-2 was found to have a pro-apoptotic effect on Hs578T cells. Our results suggest that IGFBP-2-induced gene expressions are of functional significance for proliferation, cell adhesion, cell migration and apoptosis, and showed that IGFBP-2 can promote apoptosis in tumor cells independent of IGF.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
K. Miyako, L. J. Cobb, M. Francis, A. Huang, B. Peng, J. E. Pintar, H. Ariga, and P. Cohen
PAPA-1 Is a Nuclear Binding Partner of IGFBP-2 and Modulates Its Growth-Promoting Actions
Mol. Endocrinol., February 1, 2009; 23(2): 169 - 175.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
C. N Perera, H. G Chin, N. Duru, and I. G Camarillo
Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression
J. Endocrinol., November 1, 2008; 199(2): 221 - 233.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
C. Fottner, S. Sattarova, K. Hoffmann, G. Spottl, and M. M Weber
Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers {alpha}-fetoprotein and human chorionic gonadotropin
Eur. J. Endocrinol., September 1, 2008; 159(3): 317 - 327.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Endocrinology.